448
Leav, I. and others, 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology, 154 (3), 863–870; Horti, J. and others, 1998. A phase 2 study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports, 5 (4), 893–896; Franklin, R.B. and others, 1997. Prolactin regulation of mitochondrial aspartate aminotransferase and proteinkinase C Molecular and Cellular Endocrinology, 127 (1), 19–25; Janssen, T. and others, 1996. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer, 77 (1), 144–149; Janssen, T. and others, 1995. Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer, (frans) Acta Urol Belg, 63 (1), 7-14; Oliver, R.T. and others, 1995. New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur. J. Cancer, 31A (6), 859–860; Rana, A. and others, 1995. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur. J. Cancer, 31A (6), 871–875.